HER2 status may also influence chemotherapy sensitivity as proposed by Gennari et al [29] that focused on the adjuvant setting showing that the added benefits of adjuvant chemotherapy with anthracyclines seems to be reserved to breast cancer harboring HER2 overexpression or amplification. Here, ERBB2 is linked to breast carcinoma.